









BBA - Biomembranes xxx (2017) xxx-xxx
Contents lists available at ScienceDirect
BBA - Biomembranes
journal homepage: www.elsevier.com
Functional reconstitution of human equilibrative nucleoside transporter-1 into styrene
maleic acid co-polymer lipid particles
Shahid Rehan ⁠a, Ville O. Paavilainen ⁠b, Veli-Pekka Jaakola ⁠a⁠, ⁠⁎
a Oulu Biocenter and Faculty of Biochemistry and Molecular Medicine, University of Oulu, P.O.Box 3000, FI-90014, Oulu, Finland
b Institute of Biotechnology, University of Helsinki, 00014 Helsinki, Finland






A B S T R A C T
The human equilibrative nucleoside transporter-1 (hENT1) is important for the entry of anti-cancer and anti-viral
nucleoside analog therapeutics into the cell, and thus for their efficacy. Understanding of hENT1 structure-func-
tion relationship could assist with development of nucleoside analogs with better cellular uptake properties.
However, structural and biophysical studies of hENT1 remain challenging as the hydrophobic nature of the pro-
tein leads to complete aggregation upon detergent-based membrane isolation. Here we report detergent-free re-
constitution of the hENT1 transporter into styrene maleic acid co-polymer lipid particles (SMALPs) that form
a native lipid disc. SMALP-purified hENT1, expressed in Sf9 insect cells binds a variety of ligands with a sim-
ilar affinity as the protein in native membrane, and exhibits increased thermal stability compared to deter-
gent-solubilized hENT1. hENT1-SMALPs purified using FLAG affinity M2 resin yielded ~ 0.4 mg of active and
homogenous protein per liter of culture as demonstrated by ligand binding, size-exclusion chromatography and
SDS-PAGE analyses. Electrospray ionization mass spectrometry (ESI-MS) analysis showed that each hENT1 lipid
disc contains 16 phosphatidylcholine (PC) and 2 phosphatidylethanolamine (PE) lipid molecules. Polyunsatu-
rated lipids are specifically excluded from the hENT1 lipid discs, possibly reflecting a functional requirement for
a dynamic lipid environment. Our work demonstrates that human nucleoside transporters can be extracted and
purified without removal from their native lipid environment, opening up a wide range of possibilities for their
biophysical and structural studies.
1. Introduction
Nearly 20–30% of the human genome encodes for integral mem-
brane proteins (IMPs), a class of proteins that require lipid membranes
to maintain their structure and function. IMPs include ion channels,
membrane-bound receptors, and transporters, with many IMPs acting
as important therapeutic targets—approximately 50% of all commer-
cially available drugs directly or indirectly target IMPs [1]. Nucleo-
side transporters are a physiologically important subset of IMPs that
mediate transport of nucleosides involved in signaling [2,3] and cellu-
lar DNA/RNA synthesis [4]. Nucleoside transporters are also involved
in cellular uptake of anti-cancer and anti-viral nucleoside analog ther-
apeutics [5,6]. Mammalian cells contain two families of nucleoside
transporters—SLC28 and SLC29—with different nucleoside binding
specificities [4,7]. Human equilibrative nucleoside transporter-1
(hENT1) is a member of the SLC29 family and has been shown to trans-
port adenosine, uridine, and thymidine. hENT1 also plays a critical role
in the transport of several different chemotherapies such as gemcitabine
and cisplatin [5,8]. Expression level of hENT1 is regulated to match the
metabolic need of nucleosides uptake in proliferating cells, and it serves
as a biomarkers for certain types of cancers [9,10].
Gaining an understanding of the structure and function of hENT1
is of significant interest both for understanding its diverse physiolog-
ical functions and pathological functions as well as for drug discov-
ery efforts—understanding how nucleoside analogs interact with hENT1
could facilitate development of compound with better uptake proper
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ties. However, IMP purification in functional form remains one of the
biggest challenges in studying membrane protein structure and func-
tion. These studies are often hampered by the hydrophobic nature of
IMPs, which leads to aggregation upon isolation from lipid bilayers. Tra-
ditional methods of membrane protein purification use detergents or
amphipols for extraction from lipid membranes [11,12]. However, re-
moval from the native lipid environment can be destabilizing, leading
to the loss of physiological properties and eventual protein aggrega-
tion. In addition, extended incubation in detergents can induce aggre-
gation caused by the presence of low concentrations of free detergent
monomers that stabilize more open, aggregation-prone protein confor-
mations [13]. Attempts to add back lipids such as through reconstitu-
tion into liposomes or lipid bilayers may increase protein stability but
these processes are labor-intensive and time consuming [14]. Further-
more, due to their large size and light scattering properties liposomes
are incompatible with many modern biophysical techniques. For some
IMPs, reconstitution into membrane scaffold protein (MSP)-containing
nanodiscs has enabled successful structural and functional characteriza-
tion free from the complications of detergent micelles and free deter-
gent species [15]. However, such studies require detergent screening,
solubilization, and purification prior to reconstitution, with additional
optimizations such as choice of MSP protein, lipid-to-protein ratio, and
method of detergent removal to initiate reconstitution [16].
A novel method for membrane solubilization and IMP encapsulation
was recently described [17]. This method is based on the use of a chem-
ically stable, biocompatible, and readily available styrene maleic acid
copolymer (SMA). Active SMA is prepared by hydrolysis of the anhy-
drated SMA polymer under acidic conditions [18]. Two commercially
available variants of SMA contain different ratios of styrene to maleic
acid (2:1 or 3:1 ratios), and can differ in their ability to solubilize par-
ticular membrane proteins [17]. SMA is a highly amphipathic mole-
cule that can self-assemble into disc-like structures of 10–12 nm in di-
ameter, and capture membrane proteins within a native lipid environ-
ment [17,19,20]. The resulting SMALPs (also called native nanodiscs
or lipid discs) are fully water-soluble assemblies that contain IMPs to-
gether with their respective native lipids [21]. SMALPs are emerging
as a substitute for detergents in biophysical and structural characteri-
zation of membrane proteins that are prone to lose their native fold in
complex detergent micelles [22]. Furthermore, recent advances in crys-
tal-free structural characterization of membrane proteins using cryo-EM
single particle methods [23–25] have opened new possibilities for study-
ing SMALP-encapsulated IMP complexes.
Inspired by these studies we have evaluated the potential of SMA
technology for functional reconstitution of the hENT1 transporter. Here,
we report a simple protocol for detergent-free solubilization, and pu-
rification of hENT1 embedded in SMALPs. We demonstrate that the
hENT1-SMALPs can be purified in a homogenous, stable form and bind
hENT1 ligands with comparable affinities to the transporter in Sf9 mem-
branes. Thus, hENT1-SMALPs provide a powerful tool for future high
content chemical screens to identify and biophysically characterize new
hENT1 inhibitors. Furthermore, hENT1-SMALPs will likely be suitable
for structural studies into structure-function relationships using single
particle cryo-EM approaches.
2. Materials and methods
2.1. Materials
All restriction enzymes and Phusion DNA polymerase were pur-
chased from New England Biolabs, USA. Anti-FLAG M2 affinity resin,
SLC29A1 antibody produced in rabbit (HPA012384) and asolectin were
purchased from Sigma, USA. Goat anti-rabbit IgG-horseradish perox-
idase (RPN4301) and PVDF membrane were purchased from Amer-
sham™, UK. ECL Plus Western detection reagents were from Thermo
Fisher, USA. Insect cell culture media was from Lonza, Switzerland.
S-(4-Nitrobenzyl)-6-thioinosine (NBMPR), dilazep and dipyridamole
were purchased from Tocris Bioscience, UK. Tritium-labeled NBMPR
([⁠3H]NBMPR) with a specific activity of 8.43 Ci/mmol was purchased
from Moravek Biochemicals, USA. GF/B glass filter 96-well plates were
purchased from Millipore, USA. SMA polymer (XIRAN® SZ30010) was
from Polyscope Polymers, Netherlands.
2.2. Preparation of styrene-maleic acid copolymer (SMA)
Pre-hydrated poly (styrene-co-maleic) at a ratio of 2:1 (SZ30010,
Mol. wt 10,000 g/mol, maleic context approx. 31% wt) was provided by
Polyscope (Netherlands) as a 25% (w/v) sodium salt solution. Polymer
was precipitated with concentrated HCl, washed 5 times with 100 mM
HCl, and lyophilized overnight. A stock solution of SMAs (6%, w/v)
was made in a buffer containing 10 mM HEPES, pH 8.0, and stored at
− 20 °C. Hydrolysis was confirmed by FTIR analysis as descried previ-
ously [26].
2.3. Cloning and baculovirus expression of hENT1
hENT1 cDNA (NCBI gene ID: 2030) was PCR amplified using
hENT1-specific primers containing sites for Sph I and KpnI restriction en-
zymes, and cloned into a pFastBac1 vector. All constructs were sequence
verified.
Insect cell expression was carried out as described previously [27].
Briefly, the pFastBac1 vector containing the full-length hENT1 gene
was transformed into competent DH10Bac cells and plated out onto LB
plates containing 10 μg/ml Tetracycline, 50 μg/ml kanamycin, 7.5 μg/
ml gentamycin, and 40 μg/ml Blue-gal, and incubated for two days
at 37 °C. The recombinant bacmid DNA was extracted using standard
methods and used to co-transfect insect cells using Invitrogen's protocol.
Recombinant baculovirus containing hENT1 was passaged three times
to generate a high titer virus stock. Sf9 cells at density of 1.5 × 10⁠6 per
ml were virally transduced with an MOI of 2 and protein expression was
achieved by incubating the cells at 27 °C for two days. Cells were col-
lected by centrifugation at 1000g for 5 min and disrupted in lysis buffer
(50 mM HEPES, pH 8.0, 500 mM NaCl, 5 mM EDTA, and 1 mM PMSF)
by dounce homogenization. Membranes were prepared using method
described previously [27]. Briefly, unbroken cells were separated by
centrifugation at 1000g for 10 min and membranes were isolated by ul-
tracentrifugation at 235,000g for 1 h. Isolated membranes were resus-
pended in ice-cold buffer (50 mM HEPES, pH 8.0, 500 mM NaCl) and
washed 3- to 4-times. Finally membranes were resuspended in storage
buffer (50 mM HEPES, pH 8.0, 500 mM NaCl and 40% glycerol) and
stored at − 70 °C until further analysis.
2.4. Solubilization of hENT1expressed in Sf9 membranes
hENT1-expressing Sf9 membranes were diluted to a final protein
concentration of 3 mg/ml in buffer containing 50 mM HEPES, pH 8.0,
500 mM NaCl, and 10% glycerol, and then solubilized with 0.25%
SMA in the presence of 0.2% cholesteryl hemisuccinate CHS (w/v) at
°C for 20 h. Insoluble protein was separated by untracentrifugation
at 235,000g for 1 h, and supernatant containing SMALP-reconstituted
hENT1 was collected for further analysis. Detergent solubilization was
carried out as described previously [27].
2.5. Preparation of crude liposomes
Proteoliposomes containing functional hENT1 were prepared ac-
cording to the methods of Vickers et al. [28] with the following modi-
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lized with 2% n-octyl-β-d-glucoside (β-OG) in a solubilization buffer
(50 mM HEPES, pH 8.0, 500 mM NaCl, and 10% glycerol) for 2 h at
4 °C, followed by ultracentrifugation at 235,000g for 1 h to separate
the insoluble membrane fraction. Solubilized hENT1 was then supple-
mented with asolectin and CHS solubilized with 2% β-OG at a molar ra-
tio of 60:30:10, and incubated on ice for 30 min. Removal of the deter-
gent and formation of crude liposomes was achieved by first diluting the
reaction mixture below the CMC of β-OG (0.5%) and then completely
removing detergent by dialyzing overnight at 4 °C Samples were ultra-
centrifuged at 235,000g for 1 h to collect the concentrated liposomes,
which were flash frozen in liquid nitrogen, and stored at − 70 °C until
further analysis.
2.6. Saturation and competition binding experiments
The saturation binding experiments were performed as described
previously [27]. Briefly, 5–10 μg of isolated membrane, proteoliposome,
and either SMA-solubilized or purified hENT1-SMALPs were diluted
in transport buffer (10 mM Tris-HCl, pH 8.0) and incubated with in-
creasing concentrations of [⁠3H]NBMPR, ranging from 0.125–30 nM, for
40 min at 22 °C. In order to assess non-specific ligand binding, identical
reactions were prepared in the presence or absence of 10 μM unlabeled
NBMPR or dipyridamole. Unbound ligand was removed by washing the
reaction mixture with ice-cold transport buffer on 0.2 μm 96-well fil-
ter plates (Millipore) under vacuum. Plates were dried at room temper-
ature and radioactivity was measured using a MicroBeta TriLux scin-
tillation counter (Millipore). The amount of [⁠3H]NBMPR specifically
bound to hENT1 was calculated as the difference between the amount of
[⁠3H]NBMPR that bound in the presence and absence of 10 μM unlabeled
NBMPR or dipyridamole. The dissociation constant K⁠d and B⁠max were
calculated by fitting the experimental data to one site-specific binding
equation using non-linear regression with Graphpad prism software.
For competition binding assays, protein was incubated with increas-
ing concentrations of either unlabeled NBMPR, dipyridamole or dilazep
for 10 min before adding 2.5 nM [⁠3H]NBMPR. Apparent inhibition con-
stants (K⁠i values) were calculated using the Cheng and Prusoff equation
[29].
Where K⁠i is the equilibrium dissociation constant for unlabeled in-
hibitor, IC50 is the concentration causing 50% inhibition; L is the con-
centration of the radioligand, and K⁠d is the equilibrium dissociation con-
stant for the radioligand.
2.7. Analysis of hENT1 stability in SMALPs
Stability of hENT1 in SMALPs was monitored using a radioli-
gand-binding assay as described previously [27,30]. Briefly, 100 μl of
hENT1 samples solubilized with either 0.25% (w/v) SMA or 1% of de-
tergent (n-dodecyl-β-d-maltopyranoside (DDM) and decyl-β-DM) were
incubated at temperatures ranging from 4 to 80 °C in 5 °C increments
in a gradient thermocycler for 30 min. Control samples were kept on
ice. After heating, samples were chilled on ice for 5 min and centrifuged
at 235,000g for 30 min at 4 °C. Sf9 membrane samples were processed
without centrifugation. [⁠3H]NBMPR binding activities were then mea-
sured by normalizing the data with the control sample (from 4 °C).
Melting temperatures were calculated by fitting the experimental data
to a non-linear Boltzmann sigmoidal equation using GraphPad Prism
software.
2.8. Purification and characterization of SMALP-reconstituted hENT1
Purification of hENT1-SMALPs was carried out from Sf9 membrane
isolated from 1 L of cell culture. Solubilization was carried out essen-
tially as described above. The soluble fraction was collected and bound
to 1 ml of pre-equilibrated FLAG M2 affinity resin overnight at 4 °C with
mild agitation. FLAG M2 affinity resin with bound hENT1-SMALPs was
loaded onto an empty Bio-Rad chromatography column, and the resin
was then washed with 10–20 column volumes of wash buffer (50 mM
HEPES, pH 8.0, 500 mM NaCl, and 5% glycerol). Finally, hENT1 was
eluted with 100 μg/ml of FLAG peptide in elution buffer (20 mM HEPES
pH 8.0, 500 mM NaCl and 5% glycerol). Concentration of hENT1 was
determined spectrophotometrically using an extinction coefficient of
57,005 M⁠− 1 cm⁠− 1 at 280 nm. Final yield of purified hENT1 was quan-
tified as 0.4 mg per liter of Sf9 culture.
Purified hENT1-SMALP protein was separated using 12% SDS-PAGE
and visualized by both Coomassie Blue staining and immunoblotting us-
ing anti-His antibody and anti-SLC29A1 antibodies. Homogeneity of the
purified protein was assessed by size-exclusion chromatography analy-
sis. Briefly, purified protein was injected into Enrich SEC 650 10 × 300
column (BioRad) using ÄKTAPurifier system (GE health). Functional in-
tegrity of the protein was analyzed using a radioligand-binding assay as
described above.
2.9. Lipid analysis
Identification and quantification of hENT1-SMALP lipids was carried
out by ESI-MS analysis. Briefly, lipids from SMA-solubilized total mem-
branes and purified hENT1-SMALPs were extracted according to the
method as described earlier [31] and dissolved in chloroform:methanol
(1:2 v/v). Immediately prior to mass spectrometry, NH⁠4OH was added
to a final concentration of 1% to facilitate ionization. Aliquots were in-
fused into the electrospray source of a triple quadrupole mass spectrom-
eter (Agilent 6490 Triple Quad LC/MS with iFunnel Technology; Agilent
Technologies, Santa Clara, CA) at flow rate of 10 μl/min, and mass spec-
tra were recorded using both positive and negative ionization modes,
and several lipid class-specific MS/MS scanning modes [32]. Mass spec-
tra were processed with the MassHunter software (Agilent Technolo-
gies, Inc. California, USA), and the procedures of the quantitative data
analysis utilizing LIMSA software as described previously [33]. Phos-
phatidylcholines (PCs, detected as precursors of m/z 184, P184) and
phosphatidylethanolamines (PEs, detected as neutral loss of 141 mass
units, NL141) species could be detected both in sample prepared from
the purified protein and in the isolated membranes. To support identi-
fication of the acyl chain assembly of the lipid species isolated with the
hENT1 protein, the fatty acid composition of the preparation was deter-
mined by gas chromatography essentially as detailed in [34].
3. Results and discussion
3.1. SMA solubilization of hENT1
To test the ability of SMA to solubilize functional hENT1, we used
SMA to extract hENT1 from Sf9 cells overexpressing the protein. Our
initial experiments indicated that SMA is capable of efficiently ex-
tracting hENT1 from Sf9 membranes, but that solubilization at room
temperature resulted in significant protein degradation (Supplementary
Fig. S1a). Therefore, we carried out all subsequent solubilization ex-
periments at 4°C for overnight (12- to 18-hours) using 0.25% SMA,
which resulted in approximately 20% solubilization efficiency (data not
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tions in excess of 0.5% (w/v), resulted in efficient hENT1 extraction, the
solubilized transporter completely lacked ability to bind [⁠3H]NBMPR
(Supplementary Fig. S1b). This was unexpected as many previous stud-
ies reported the use of 2–3% SMA for solubilizing diverse IMPs in
functional form at room temperature followed by affinity purification
[17,35]. We propose that at higher concentrations either the amphi-
pathic SMA polymer interacts with the hydrophobic NBMPR ligand, or
the highly positively charged carboxyl group of the SMA polymer inter-
acts with charged groups on the hENT1 surface, disrupting the structure
and rendering hENT1 non-functional.
In an effort to preserve the hENT1functionality, we added CHS and
asolectin to SMA extraction, as our earlier study showed that these lipids
stabilize detergent-solubilized hENT1 [27]. Here we found that addition
of CHS and asolectin did not increase the solubilization efficiency, possi-
bly due to competition between these lipids and native membrane lipids
for solubilization by SMA. However, addition of both CHS and asolectin
improved the ability of hENT1 to bind [⁠3H]NBMPR when solubilized
with 0.25% (w/v) SMA (Supplementary Fig. S1a). It is unclear whether
CHS and asolectin affect SMA-solubilized hENT1 function by directly in-
teracting with hENT1, or if these lipids “chemically tune” the SMALP
assembly process by increasing protein thermal stability. Cholesterol is
known to enhance the lipid bilayer packing by occupying grooves and
cavities formed by kinks in unsaturated fatty acid tails [36] and may
stabilize IMPs in a similar way. In all subsequent experiments we used
0.25% (w/v) SMA supplemented with 0.2% CHS (w/v) for hENT1 solu-
bilization.
3.2. hENT1-SMALP inhibitor binding
To examine whether SMALPs are capable of encapsulating hENT1
in a functional state indicative of native folding we carried out satura-
tion binding experiments of SMA-solubilized hENT1 with [⁠3H]NBMPR
(Fig. 1a, Supplementary Fig. S3A). These studies, carried out in the pres-
ence and absence of a large excess of pyridamole to control for non-spe-
cific [⁠3H]NBMPR binding, demonstrated saturable [⁠3H] NBMPR bind-
ing with a K⁠d of 3.0 ± 0.4 nM, a value comparable to earlier studies
(1.2 ± 0.2 nM) using hENT1 expressed in Sf9 insect cells [27]. Similarly,
hENT1-SMALPs retained affinity for the structurally unrelated inhibitors
dilazep and dipyridamole. Consistent with our previous study [37]
we observed monophasic behavior of these inhibitors in [⁠3H]NBMPR
competition binding experiments where we obtained K⁠i values of
4.0 ± 0.4 nM, 34.0 ± 1.0 nM, and 527.4 ± 3.0 nM for unlabeled
NBMPR, dilazep, and dipyridamole, respectively (Fig. 1b). These in-
hibitor constants are 4- to 33-fold higher than previously published
values obtained using membrane vesicles and reconstituted proteolipo-
somes (Table 1). The increase in K⁠d and K⁠i may reflect small struc-
tural re-arrangements during solubilization and lipid disc formation.
[⁠3H]NBMPR binding experiments with empty SMA (without hENT1)
demonstrated only negligible binding, further suggesting a slight de-
crease in specific hENT1 ligand binding activity (Supplementary Fig.
S3b). Another possible explanation is that the highly negatively charged
SMA carboxylic groups may promote hENT1 to adopt a non-phys-
iological protein conformation at higher SMA concentrations.
Fig. 1. Functional and thermostability analysis of hENT1-SMALPs. (a) Equilibrium bind-
ing of [⁠3H]NBMPR (0.12 nM–30 nM) to SMA-solubilized hENT1 transporter. Results are
presented as the amount of specifically bound [⁠3H]NBMPR (after subtraction of non-specif-
ically bound fraction) as a function of free [⁠3H]NBMPR. Each data point represents an av-
erage of at least three measurements. Three experiments gave similar results yielding a K⁠d
of 3.0 ± 0.4 nM. (b) [⁠3H]NBMPR competition binding by different inhibitors. SMA-solubi-
lized hENT1 incubated with 3.5 nM [⁠3H] NBMPR alone or together with either unlabeled
NBMPR, dilazep or dipyridamole over a concentration range of 0.01 pM to 100 μM. Re-
sults are shown as the percentage of [⁠3H] NBMPR bound as a function of the logarithm of
the concentration of unlabeled competitor. The amount of [⁠3H]NBMPR that bound in the
absence of inhibitors was taken as 100% binding. Each point is the average of at least three
measurements. Two independent experiments showed similar results yielding K⁠i values of
4.0 ± 0.4 nM, 34.0 ± 1.0 nM, and 527 ± 3 nM for NBMPR, dilazep and dipyridamole, re-
spectively. (c) Thermostability analysis of hENT1 in different environments. The protein
was solubilized with either SMALPs or detergent and heated in a thermocycler for 30 min
at 4 °C–80 °C and [⁠3H]NBMPR binding activities were subsequently measured as described
in the methods section. All experiments were repeated at least three times. Each data point
is the average of at least three measurements.
Table 1
Pharmacological characterization of hENT1 in different membrane systems.
Inhibitor/drug [K ⁠i (nM)] SMALP⁠2 Sf9 membrane⁠a Proteoliposome ⁠b LMNG⁠a DM⁠a
[⁠3H]NBMPR 4.0 ± 0.4 1.0 ± 0.2 1.0 ± 0.3 7.0 ± 2.0 10.0 ± 0.5
Dilazep 34.0 ± 1.0 3.0 ± 0.1 4.0 ± 0.5 37.0 ± 1.0 –
Dipyridamole 527.4 ± 3.0 16.0 ± 1.0 33.0 ± 3.3 303.0 ± 1.0 –
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Nevertheless, the rank order of hENT1 affinities between the tested in-
hibitors is consistent with all previous studies [28,37,38], suggesting
that the overall activity of hENT1 in the SMALP platform is compara-
ble to physiological activity, and that SMALPs can be used for further
biophysical investigations of hENT1 and possibly other nucleoside trans-
porters.
When compared to reconstitution in detergents, hENT1-SMALPs per-
form similarly. hENT1 reconstituted in SMALPs retained pharmaco-
logical properties similar to those in lauryl maltose neopentyl glycol
(LMNG) and DM detergents, although the DM-solubilized hENT1 had
nearly 4-fold low binding affinity for NBMPR compared to membrane
vesicles (Table 1, Supplementary Fig. S1, c-d). hENT1 reconstitution in
SMALPs is more efficient than solubilization in DM detergent. However,
given the potential interference of detergents with many biophysical
techniques, detergent-induced destabilization of membrane proteins and
the difficulties in removing detergents with very low CMCs, the SMALP
platform becomes an attractive choice for solubilizing hENT1 for func-
tional studies.
3.3. hENT1-SMALP thermostability
To further verify the correct folding of SMALP-embedded hENT1, we
investigated the thermal stability of hENT1-SMALPs using the above-de-
scribed radioligand-binding assay [22]. The temperature dependent de-
crease in the ability of hENT1-SMALPs to bind [⁠3H]NBMPR was used
to indicate the loss of correct folding. The obtained binding data at dif-
ferent temperatures was fitted to a sigmoid curve describing the ther-
motrophic transition from folded to the unfolded or aggregated form of
the protein. From this plot, we defined an apparent melting temperature
(T⁠m) as the temperature at which radioligand-binding activity dropped
to 50% of maximum. This analysis revealed an apparent T⁠m of 45 °C for
the hENT1 transporter in Sf9 membranes (Fig. 1c). Solubilization with
either DDM or DM resulted in a marked decrease in thermostability (T⁠m
of 30 °C and 31 °C, respectively). However, the SMA-solubilized hENT1
retained thermal stability closer to the apparent melting temperature in
Sf9 cell membranes (T⁠m of 37 °C and 45 °C, respectively.
A common problem associated with detergent solubilization of mem-
brane proteins is destabilization of native protein structure in the sol-
ubilized state, which is likely caused by varying degrees of delipida-
tion [12,39]. In the case of SMALPs, annular lipids become encapsulated
and are retained during assembly, thereby decreasing the likelihood
of activity loss due to lipid depletion [40,41]. This effect was clearly
observed when comparing hENT1-SMALPs with detergent-solubilized
hENT1 (Fig. 1c). Yet, an even greater degree of thermostabilization was
achieved by solubilization with LMNG [27]. However, while this ap-
pears to suggest that LMNG is a better choice for hENT1 characteriza-
tion, it should be noted that LMNG forms complex micelles, and due
to their extremely low critical micelle concentration (CMC ~ 0.0001%),
it is practically impossible to completely remove LMNG using conven-
tional detergent removal methods [13]. These micelle properties are
known to interfere with IMP characterization by biophysical and struc-
tural methods such as vapor-diffusion-based crystallization, single par-
ticle cryo-EM and NMR [12,13,42]. Therefore, a significant increase in
thermal stability compared to maltoside detergents makes SMALPs an
excellent choice for future structural studies on hENT1.
3.4. Analysis of purified hENT1 in SMALPs
Purification of hENT1-SMALPs was carried out from total cellular
membranes prepared from a 1 l culture of Sf9 cells infected with a
recombinant baculovirus expressing 8xHis-FLAG tagged hENT1 [27].
Following SMA-solubilization and affinity purification with FLAG M2
resin, (Supplementary Fig. S2a) the purified protein yield was estimated
as ~ 0.5 mg per liter of culture (Table 2). On SDS-PAGE, the puri-
fied protein runs as a major band at the expected molecular weight of
45 kDa with minor multimeric SDS-resistant species observed at higher
molecular weights (Fig. 2a and Supplementary Fig. S2a-b). Western
blot analysis with an isoform-specific antibody was used to verify that
these observed bands correspond to intact hENT1. The presence of a
C-terminal 8xHis tag was confirmed by probing with an anti-His an-
tibody, whereas the N-terminal FLAG tag was used for affinity purifi-
cation (Supplementary Fig. S2b). Size-exclusion chromatography analy-
sis on an Enrich SEC 650 10 × 300 column (BioRad) indicated that the
monomeric hENT1-SMALPs are homogenous and elute at approximately
130–140 kDa molecular weight (Fig. 2a, Supplementary Fig. S2c-d). We
then analyzed the functional integrity of purified hENT1-SMALPs by
[⁠3H]NBMPR binding assay, which revealed no significant loss of activ-
ity during purification (K⁠d of 8.0 ± 2.0 nM and 3.4 ± 0.4 nM for puri-
fied and solubilized hENT1-SMALPs, respectively) (Fig. 2b). Bmax de-
termination from this experiment revealed that 877 pmol/mg of hENT1
retains [⁠3H]NBMPR binding activity. This corresponds to approximately
92 ± 4% specific hENT1 activity in the final preparation (Table 2).
Furthermore, single non-saturating concentration of [⁠3H]NBMPR used
to estimated Bmax value of various fractions
Table 2
Yield and activity of hENT1-SMALPs during affinity purification steps.
Fraction Yield (mg) Purity (%) % Activity
Sf9 membrane 4.5⁠a – –
SMALPs-solubilized hENT1 1.0⁠a – –
Purified hENT1-SMALPs 0.4⁠b > 90 92 ± 4%⁠c
a Total protein estimated by BCA assay.
b hENT1-SMALPs protein was estimated using nanodrop spectrometer (280 nm).
c Estimated from the Bmax values of two independent experiments.
Fig. 2. Purification and characterization of hENT1-SMALPs. (a) Saturation binding assay
of purified hENT1-SMALPs with [⁠3H]NBMPR using the method described in the main
text. (b) Size exclusion chromatography analysis of purified hENT1-SMALPs on Enrich
SEC 650 10 × 300 column (Bio-Rad) with a flow rate of 0.5 ml/min. The relative size
of protein-SMALP complexes was estimated using elution profiles of protein standards
detected by UV detector (see supplementary Fig. S2c-d). Inset: Purified hENT1-SMALPs
monomer (*) and dimer (**) eluted during gel filtration. On SDS-PAGE monomer (►) near
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that shows 8-fold enrichment of hENT1 during purification (Supplemen-
tary Fig. S3c).
3.5. Lipids in hENT1-SMALP assembly
The composition of the surrounding lipid bilayer is important for ac-
tivity and stability of many IMPs [43–45]. We therefore, set out to es-
tablish the identity and stoichiometry of individual lipid species present
in the annular hENT1 lipid bilayer. For this purpose, we performed lipid
extraction from purified hENT1-SMALPs as well as from Sf9 membrane
derived from cells infected with a control virus that does not express
hENT1. ESI-MS/MS tandem mass spectrometry analysis revealed promi-
nent suppression of many lipid peaks by several artifact peaks arising
from the SMA polymer (data not shown), however, using a class spe-
cific scanning mode we were able to identify and quantitatively char-
acterize the PC and PE lipids species that form the main constituents
of the Sf9 cell membrane [46]. Quantitation of the phospholipid con-
tent of purified hENT1-SMALPs, using purified reference lipids, revealed
that hENT1 co-purifies as a complex with approximately 16 and 2 as-
sociated PE lipids, respectively. These findings are in good correlation
with previous reports on phospholipid inclusion with diverse purified
IMP-SMALPs (Table S3) [17]. Interestingly, the purified hENT1-SMALPs
exhibited selective enrichment of long chain PC species when compared
to SMA-solubilized Sf9 cell membrane controls (Fig. 3a). In contrast,
analysis of PE lipids species revealed complete exclusion of polyunsat-
urated lipid species that are detected in Sf9 membrane controls (Fig.
3b, Table S1). Furthermore, GC–MS analysis confirmed that purified
hENT1-SMALPs only contain saturated and monounsaturated fatty acids
(Table S2).
The physiological functions of many IMPs can be greatly influenced
by the composition of membrane lipids; while annular lipids (the first
lipid layer around an IMP) may non-specifically interact with IMPs, the
non-annular lipids selectively bind and regulate IMP function and cor-
rect folding [47]. These lipids often co-purify with proteins and can
withstand the excessive delipidation that removes most annular lipids
during detergent solubilization. Under physiological conditions, protein
conformational changes at protein-bilayer boundaries alter lipid pack-
ing which in turn is influenced by physiochemical properties of lipids
and the degree of unsaturation in their fatty acyl chains [48]. Since
polyunsaturated lipids are known to promote membrane rigidity and
plasma membrane dynamics they may have important significance for
the function of proteins with high degree of inherent conformational
flexibility such as hENT1 [49].
4. Conclusion
In this paper we have explored the potential of SMA technology
for the purification and characterization of nucleoside transporters. We
have successfully purified the hENT1 transporter in a functional form
with comparable ligand binding properties as previously reported for
the transporter reconstituted in a lipid bilayer membrane. We found that
purified hENT1-SMALPs are comparatively more stable than hENT1 sol-
ubilized in detergents such as DDM and DM and that the lipid composi-
tion of SMALP-hENT1 is highly enriched in PC lipids with saturated and
monounsaturated fatty acids. Our data suggests that hENT1-SMALPs are
an excellent platform for biophysical and structural characterization of
the transporter.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2017.02.017.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
Fig. 3. Analysis of the lipid content of hENT1-SMALP particles. (a) (ESI-MS/MS analysis of the lipid content of SMALPs-solubilized Sf9 membranes and purified hENT1-SMALPs. Lipid
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